<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
     xmlns:admin="http://webns.net/mvcb/"
     xmlns:content="http://purl.org/rss/1.0/modules/content/"
     xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
	<channel>
	<title>MetaFilter posts tagged with bigpharma</title>
	<link>http://www.metafilter.com/tags/bigpharma</link>
	<description>Posts tagged with 'bigpharma' at MetaFilter.</description>
	<pubDate>Fri, 14 Sep 2007 18:05:31 -0800</pubDate> <lastBuildDate>Fri, 14 Sep 2007 18:05:31 -0800</lastBuildDate>

	<language>en-us</language>
	<docs>http://blogs.law.harvard.edu/tech/rss</docs>
	<ttl>60</ttl>
	<item>
		<title>Thin Times</title>
		<link>http://www.metafilter.com/64706/Thin%2DTimes</link>
		<description> &lt;a href=&quot;http://www.sharecast.com/cgi-bin/sharecast/story.cgi?story_id=1586518&quot;&gt;Struggling &lt;/a&gt;British biotech firm &lt;a href=&quot;http://www.pharmalive.com/News/index.cfm?articleid=474624&amp;categoryid=40&quot;&gt;Vernalis     &lt;/a&gt; reports &quot;striking&quot; weight loss among patients taking its new obesity drug, &quot;&lt;a href=&quot;http://www.cambridge-news.co.uk/business/news/2007/09/14/37681654-68dc-431d-84be-239882bb0b1e.lpf&quot;&gt;V24343&lt;/a&gt;&quot;.  </description>
		<guid isPermaLink="false">tag:metafilter.com,2007:site.64706</guid>
		<pubDate>Fri, 14 Sep 2007 18:05:31 -0800</pubDate>
		<category>bigpharma</category>
		<category>obesity</category>
		<category>pill</category>
		<category>vernalis</category>
		<category>weightloss</category>
		<dc:creator>chuckdarwin</dc:creator>
	</item>
      <item>
		<title>Oxycontin for the rich, heroin for the poor...</title>
		<link>http://www.metafilter.com/48802/Oxycontin%2Dfor%2Dthe%2Drich%2Dheroin%2Dfor%2Dthe%2Dpoor</link>
		<description> &quot;Well, a lot of people have said DEA is in the dark on these issues, &lt;a href=&quot;http://www.fda.gov/ohrms/dockets/ac/03/transcripts/3978T1.DOC&quot;&gt;but that is a little bit much.&lt;/a&gt;&quot; (.doc; long) Despite a power outage, an FDA-lead panel discusses how to manage abuse of the &lt;a href=&quot;http://www.cnn.com/2003/SHOWBIZ/10/10/rush.limbaugh/&quot;&gt;infamous&lt;/a&gt; opiod painkiller &lt;a href=&quot;http://www.fda.gov/cder/drug/infopage/oxycontin/oxycontin-qa.htm&quot;&gt;OxyContin&lt;/a&gt;. &lt;a href=&quot;http://www.pharma.com/&quot;&gt;Purdue Pharma&lt;/a&gt;, its sole manufacturer, had tried to bring its more powerful successor &lt;a href=&quot;http://www.dphhs.mt.gov/hpsd/medicaid/medicaid2/pdf/dossierpalladone.pdf&quot;&gt;Palladone&lt;/a&gt; (.pdf) to the market, before &quot;dosage jump&quot; issues lead to the drug &lt;a href=&quot;http://www.washingtonpost.com/wp-dyn/content/article/2005/07/13/AR2005071302286.html&quot;&gt;being pulled&lt;/a&gt; by the FDA. Meanwhile, trucks loaded with $3mil dollars of &quot;oxys&quot; continue to get hijacked for a $15mil street turnover, despite GPS tracking and other high-tech security measures used for cigarette distribution. Doctors invariably shuffle pills sideways despite &lt;a href=&quot;http://72.14.203.104/search?q=cache:eSjm4FAdfm0J:www.fda.gov/ohrms/dockets/ac/03/transcripts/3978T1.DOC%20%20oxycontin%20truck%20hijacking&amp;hl=en&amp;gl=us&amp;ct=clnk&amp;cd=28&quot;&gt;tamper-proof presciption pads&lt;/a&gt; (long). Purdue only stops selling more profitable and addictive &lt;a href=&quot;http://headaches.about.com/bl-purd-051001.htm&quot;&gt;double-doses of OxyContin&lt;/a&gt; after government pressure. On the level of the street, addicts who find themselves too tolerant to the drug find their needs more than adequately met when they can buy many more hits of heroin for the same cost. Philadelphia-based writer Jeff Deeney outlines some of these fascinating &lt;a href=&quot;http://blog.myspace.com/index.cfm?fuseaction=blog.view&amp;friendID=312074&amp;blogID=83118663&quot;&gt;issues and more&lt;/a&gt; as he looks into how race, cost, manufacturing and distribution factors in OxyContin abuse invariably drive the addict to cheaper and more easily accessible heroin.  </description>
		<guid isPermaLink="false">tag:metafilter.com,2006:site.48802</guid>
		<pubDate>Thu, 02 Feb 2006 08:00:23 -0800</pubDate>
		<category>BigPharma</category>
		<category>Dittoheads</category>
		<category>Drug</category>
		<category>DrugAbuse</category>
		<category>Drugs</category>
		<category>OxyContin</category>
		<category>Palladone</category>
		<category>Pharmaceuticals</category>
		<category>Purdue</category>
		<dc:creator>Rothko</dc:creator>
	</item>
      <item>
		<title>How to think about prescription drugs.</title>
		<link>http://www.metafilter.com/36652/How%2Dto%2Dthink%2Dabout%2Dprescription%2Ddrugs</link>
		<description>&lt;a href="http://newyorker.com/critics/atlarge/?041025crat_atlarge"&gt;How to think about prescription drugs.&lt;/a&gt; Malcolm Gladwell&apos;s latest piece in&lt;i&gt; The New Yorker&lt;br&gt;&lt;small&gt;The emphasis of the prescription-drug debate is all wrong. We&apos;ve been focussed on the drug manufacturers. But decisions about prevalence, therapeutic mix, and intensity aren&apos;t made by the producers of drugs. They&#8217;re made by the consumers of drugs.&lt;/small&gt;&lt;/i&gt;&lt;small&gt;&lt;/small&gt;&lt;/small&gt;  </description>
		<guid isPermaLink="false">tag:metafilter.com,2004:site.36652</guid>
		<pubDate>Sun, 31 Oct 2004 21:03:21 -0800</pubDate>
		<category>bigpharma</category>
		<category>drugs</category>
		<category>gladwell</category>
		<category>health</category>
		<category>healthcare</category>
		<category>newyorker</category>
		<category>pharmaceuticals</category>
		<category>prescription</category>
		<dc:creator>trharlan</dc:creator>
	</item>
      <item>
		<title>An Epidemic of Globalization?</title>
		<link>http://www.metafilter.com/29941/An%2DEpidemic%2Dof%2DGlobalization</link>
		<description> Haunted by a truly global epidemic, perhaps it is time to consider the &lt;a href=&quot;http://www.pchrd.dost.gov.ph/PCHRD/PublicInterest/projects/Health%20R&amp;D%20Papers/globalization.htm&quot; title=&quot;&apos;The other side of globalization&#8230; A threat to public health?&apos; by Alan B. Feranil, PhD&quot;&gt;effects of globalization &lt;/a&gt;on the spread of diseases like AIDS.  In addition to making it easier for disease to achieve global prevalence, global economics reduce funding for public health by &lt;a href=&quot;http://www.msf.org/content/page.cfm?articleid=C812297E-9FCF-40AA-8CBBE08B573AC631&quot; title=&quot;In Malawi, 1 million are infected with AIDS, and 30 have access to AIDS treatments.&quot;&gt;placing treatment emphasis on those who can pay for their drugs&lt;/a&gt;, and, in the case of AIDS, may also encourage pharmaceutical companies to &lt;a href=&quot;http://www.uea.ac.uk/dev/publink/barnett/HIVAIDS%20and%20Globalization.pdf&quot; title=&quot;The more ready availability of large profits from treatments of disease in rich countries and communities has meant that &#8211; for example &#8211; there has been markedly less attention to the needs of communities and countries which have lower ability to express their needs through markets. It has been argued (Thomas 2001) that pursuit of an HIV/AIDS vaccine has been of less interest to big pharmaceutical companies. These stand to profit more from development of treatments than vaccines.&quot;&gt;pursue expensive life-long &apos;treatments&apos; rather than cures. &lt;/a&gt;  Furthermore, younger, economically depressed members of the global economy are wholly dependent on the &lt;a href=&quot;http://www.globalpolicy.org/globaliz/econ/2003/1009bushaidstest.htm&quot; title=&quot;$3 Billion for AIDS? Psyke!&quot;&gt;whim of richer nations&lt;/a&gt; for their well-being in the face of devastating epidemics.  In this case, it seems that the &lt;a href=&quot;http://www-tech.mit.edu/V121/N41/col41guest.41c.html&quot; title=&quot;Faith-Based Economics&quot;&gt;global marketplace has failed to be the holy grail &lt;/a&gt;it is so often presented as.  </description>
		<guid isPermaLink="false">tag:metafilter.com,2003:site.29941</guid>
		<pubDate>Mon, 01 Dec 2003 13:43:20 -0800</pubDate>
		<category>aids</category>
		<category>bigpharma</category>
		<category>epidemiology</category>
		<category>globalization</category>
		<category>publichealth</category>
		<dc:creator>kaibutsu</dc:creator>
	</item>
      <item>
		<title>Inventing a new disease? </title>
		<link>http://www.metafilter.com/22641/Inventing%2Da%2Dnew%2Ddisease</link>
		<description>&lt;a href="http://bmj.com/cgi/content/full/326/7379/45?ijkey=aAjYRnGz9/PFE"&gt;Inventing a new disease? &lt;/a&gt; Some experts are saying that the drug industry is trying lump women&#8217;s sexual problems under the term &#8220;female sexual dysfunction&#8221; to create a market for lucrative new Viagra-like drugs. A study in the Journal of the American Medical Association &lt;small&gt;[&lt;a href=&quot;http://jama.ama-assn.org/issues/v281n6/abs/joc80785.html&quot;&gt;abstract&lt;/a&gt;]&lt;/small&gt; found sexual dysfunction is more prevalent for women (43%) than men (31%), but &lt;a href=&quot;http://news.yahoo.com/news?tmpl=story2&amp;cid=571&amp;ncid=751&amp;e=1&amp;u=/nm/20030103/hl_nm/women_sex_dc&quot;&gt;the jury is still out&lt;/a&gt;.  </description>
		<guid isPermaLink="false">tag:metafilter.com,2003:site.22641</guid>
		<pubDate>Fri, 03 Jan 2003 09:41:37 -0800</pubDate>
		<category>bigpharma</category>
		<category>disease</category>
		<category>female</category>
		<category>sexualdicfunction</category>
		<dc:creator>gottabefunky</dc:creator>
	</item>
      
	</channel>
</rss>


